The North Wales and North West Urological Research Centre (NW2URC) was established by Professor Iqbal Shergill and Professor Stephen Fôn Hughes in January 2014.
Now embedded within MAUMSS, the NW2URC continues to provide the opportunity to develop, undertake and promote urological research in North Wales and beyond.
Overview of Research
The number of patients in the UK having surgical interventions for the treatment of benign and malignant disorders of the kidneys, prostate, and bladder is increasing annually. As such, there have been an increasing number of patients developing disease recurrence and progression, as well as post-operative complications (e.g. infection and blood clots).
Post-operative complications result in patients requiring longer hospital stays, poor patient experience and outcomes, as well as carrying additional financial constraints for the healthcare provider (NHS). Minor improvements in the monitoring of these patients following treatment could possibly have financial benefits for the healthcare provider and health benefits for the nation.
Specifically, our current research interests are divided into the following areas:
Kidney stones and kidney cancer
Benign and malignant disorders of the prostate
Clinical outcome measures (e.g. acute kidney injury, infection, bleeding, oedema, blood clots) and their relationship with biological markers
Cytokines & adhesion molecules
Early indications are that our studies may lead to important intervention relating to both treatment and diagnosis in these patients. Currently only simple non-specific blood tests are available to predict clinical outcomes and post-operative complications. No biomarker profiles are available to forecast with confidence, post- operative complications or to predict cancer recurrence and progression. Our aim therefore, is to establish such profiles.
Specifically, patients with cancer and benign conditions of the kidney, bladder and prostate will benefit as a result of increased ability in detecting recurrence and progression, allowing stricter surveillance follow-up programmes. Our research study promises to help patients (regionally and nationally) who have been diagnosed with various urological disorders, and will ultimately allow current NHS post-operative care protocols to be revised and improved; thus improving the patients’ health and well-being.
Our Research Group
Professor Iqbal Shergill (Consultant Urological Surgeon,; Director MAUMSS)
Professor Stephen Fôn Hughes (Consultant Biomedical Scientist; Director MAUMSS)
Mr Basharat Jameel (Consultant Urological Surgeon, BCUHB, Wrexham Maelor Hospital)
Mr Christian Seipp (Consultant Urological Surgeon, BCUHB, Wrexham Maelor Hospital)
Professor Kingsley Ekwueme (Consultant Urological Surgeon, BCUHB, Ysbyty Glan Clwyd)
Mr Manit Arya (Consultant Urological and Uro-oncology Surgeon, UCLH, London)
Dr Jon Power (Lecturer – Histology, University of Chester)
Dr Sohail Mushtaq (Senior Lecturer – Clinical Biochemistry, University of Chester)
Current Research Students:
Mrs Nana Yaa F. Snyper (PhD student – Benign prostate hyperplasia (BPH) & Prostate Cancer, registered with Wrexham Glyndwr University)
Mrs Tracy Knight (PhD student - Prostate Cancer, registered with Aberystwyth University)
Dr Abigail Duckett (Academic Foundation Doctor/MRes student - Non-muscle invasive bladder cancer, registered with Wrexham Glyndwr University)
Dr Bethan Hughes (Academic Foundation Doctor/MRes student - Prostate Cancer, registered with Wrexham Glyndwr University)
Completed MRes/PhD students:
Dr Sacha Moore (MRes dissertation - kidney stones), Wrexham Glyndwr University - 2021 (distinction)
Dr Chris Bell (MRes dissertation - kidney stones), Wrexham Glyndwr University - 2021 (distinction)
Dr Amarit Gill (MRes dissertation - bladder cancer), Wrexham Glyndwr University - 2021 (distinction)
Dr Peter Ella-Tongwiis (PhD – Bladder Cancer), University of Chester - 2020 (pass viva-voce)
Dr Alyson Moyes (PhD – Kidney stones), University of Chester - 2019 (pass viva-voce)
NW2URC photos (2014-2017)
Recent publications (2020-date) from the NW2URC group....
Ella-Tongwiis, P., Makanga, A., Shergill, I., & Fôn Hughes, S. (2021). Optimisation and validation of immunohistochemistry protocols for cancer research. Histology and histopathology, 36(4), 415–424. https://doi.org/10.14670/HH-18-317
Hughes SF, Moyes AJ, Lamb RM, Ella-Tongwiis P, Snyper NYF, Shergill I (2020). The role of phagocytic leukocytes following flexible ureterenoscopy, for the treatment of kidney stones: an observational, clinical pilots-study. Eur J Med Res. 2020 Dec 11;25(1):68. doi: 10.1186/s40001-020-00466-7. PMID: 33308282; PMCID: PMC7731777.
Hughes S.F., Lamb R.M., Moyes, A.J., Ella-tongwiis, P., Gill, A., Duckett, A., & Shergill, I. (2020). The Effect of Trans-urethral Resection of the Bladder Tumour (TURBT) on Routine Haematological and Biochemical Blood Tests: A Clinical-pilot Observational Study. Int J Biomed Sci, December 2020 Vol. 16 No. 4.
Duckett, A., Hughes, S., Jameel, B., Yehia, M., Seipp, C., Agarwal, S., & Shergill, I. (2020). Clinico-pathological Outcomes of Men with Initial Likert 2 Multiparametric Magnetic Resonance Imaging of the Prostate: Findings from a Case Series in a Non-teaching Hospital in UK. Journal of Advances in Medicine and Medical Research, 32(24), 63-70. https://doi.org/10.9734/jammr/2020/v32i2430752
Ella-Tongwiis P, Lamb RM, Makanga A, Shergill I, Hughes SF (2020). The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients (2020). BMC Urol. 2020 Nov 25;20(1):187. doi: 10.1186/s12894-020-00759-3. PMID: 33238953; PMCID: PMC7690172.